ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08955
0,00%
Bitcoin
66.782,22
-0,45%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Monopar Therapeutics Inc (MNPR)

  7. Monopar Therapeutics Inc (MNPR) News

MNPR

Monopar Therapeutics (MNPR)

Monopar Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:MNPR
DatumZeitQuelleÜberschriftSymbolFirma
09/05/202413h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MNPRMonopar Therapeutics Inc
09/05/202413h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNPRMonopar Therapeutics Inc
09/05/202413h00GlobeNewswire Inc.Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma PipelineNASDAQ:MNPRMonopar Therapeutics Inc
18/04/202414h00GlobeNewswire Inc.Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual MeetingNASDAQ:MNPRMonopar Therapeutics Inc
16/04/202414h00GlobeNewswire Inc.Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization FindingsNASDAQ:MNPRMonopar Therapeutics Inc
10/04/202414h00GlobeNewswire Inc.Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer PatientsNASDAQ:MNPRMonopar Therapeutics Inc
28/03/202412h00GlobeNewswire Inc.Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent DevelopmentsNASDAQ:MNPRMonopar Therapeutics Inc
07/03/202414h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNPRMonopar Therapeutics Inc
05/03/202413h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNPRMonopar Therapeutics Inc
05/03/202413h00GlobeNewswire Inc.Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma ProgramNASDAQ:MNPRMonopar Therapeutics Inc
28/02/202419h45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNPRMonopar Therapeutics Inc
27/02/202413h00GlobeNewswire Inc.Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical TrialNASDAQ:MNPRMonopar Therapeutics Inc
27/02/202412h59Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNPRMonopar Therapeutics Inc
22/02/202413h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNPRMonopar Therapeutics Inc
22/02/202413h00GlobeNewswire Inc.Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced CancersNASDAQ:MNPRMonopar Therapeutics Inc
20/02/202414h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNPRMonopar Therapeutics Inc
20/02/202414h00GlobeNewswire Inc.Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced CancersNASDAQ:MNPRMonopar Therapeutics Inc
04/01/202401h39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNPRMonopar Therapeutics Inc
04/01/202401h36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNPRMonopar Therapeutics Inc
09/11/202313h01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MNPRMonopar Therapeutics Inc
09/11/202313h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNPRMonopar Therapeutics Inc
09/11/202313h00GlobeNewswire Inc.Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent DevelopmentsNASDAQ:MNPRMonopar Therapeutics Inc
01/11/202312h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNPRMonopar Therapeutics Inc
01/11/202312h00GlobeNewswire Inc.Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual MeetingNASDAQ:MNPRMonopar Therapeutics Inc
10/10/202313h00GlobeNewswire Inc.Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities ConferenceNASDAQ:MNPRMonopar Therapeutics Inc
04/10/202301h37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNPRMonopar Therapeutics Inc
04/10/202301h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNPRMonopar Therapeutics Inc
05/09/202313h00GlobeNewswire Inc.Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:MNPRMonopar Therapeutics Inc
30/08/202323h16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNPRMonopar Therapeutics Inc
10/08/202313h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNPRMonopar Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:MNPR

Kürzlich von Ihnen besucht

BSTP
AUDIOBTC
Audius
EU
SNBX
SNCF Reseau 2.77% 13feb2...
EU
0057N
Natixis Sa null
AQSE
LGBP.GB
WisdomTree Commodity Sec...
AMEX
GUSA
Goldman Sachs Marketbeta...
TSX
IE
Ivanhoe Energy
BIT
S28309
Societe Generale Effekten
COIN
BOMBBTC
BOMB
COIN
MNTISBTC
BIT
F13620
Vontobel Financial Produ...
COIN
ACSGBP
Access Protocol
NASDAQ
VIIX
VelocityShares VIX Short...
USOTC
IMII
Inception Mining (PK)
BOV
BEES3Q
BANESTES ON
UNSW
DEGOETH
dego.finance
BIT
I07239
INTESA SANPAOLO
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten